Angiotensin-converting enzyme inhibitors are recommended as the first-line treatment to prevent hypertension-related proteinuria due to the combination chemotherapy containing bevacizumab, which might increase the release of nitric oxide, dilating blood vessels [38]. This evidence concerns the gene ACE and hypertensive disorder.